Literature DB >> 23761915

Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.

Benison Keung1, Kimberly R Robeson, Daniel B DiCapua, Jennifer B Rosen, Kevin C O'Connor, Jonathan M Goldstein, Richard J Nowak.   

Abstract

Entities:  

Keywords:  Myasthenia; Neuroimmunology; Neuromuscular

Mesh：

Substances：

Year:  2013        PMID： 23761915     DOI： 10.1136/jnnp-2012-303664

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  24 in total

1.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 2.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

3.  Thymectomy for myasthenia gravis: what's next?

Authors:  Marc de Perrot; Laura Donahoe
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy.

Authors:  Sarosh R Irani; Jeffrey M Gelfand; Brianne M Bettcher; Neel S Singhal; Michael D Geschwind
Journal:  JAMA Neurol       Date:  2014-07-01       Impact factor: 18.302

Review 5.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

6.  Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Richard J Nowak; Kevin C O'Connor
Journal:  JCI Insight       Date:  2017-09-07

7.  Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses.

Authors:  Ruoyi Jiang; Miriam L Fichtner; Kenneth B Hoehn; Minh C Pham; Panos Stathopoulos; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  JCI Insight       Date:  2020-07-23

Review 8.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

Review 9.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis.

Authors:  João Peres; Rita Martins; José Delgado Alves; Ana Valverde
Journal:  Porto Biomed J       Date:  2017-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.